30-day average of 22 articles ยท scale โ100 to +100
Across 22 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Intuitive Surgical news is Somewhat Bullish (+37)
on a scale from โ100 to +100.
That is down 7 points from the previous 30 days (+44).
๐ Worldwide procedures grew 14%, with international markets up 20%.
๐ U.S. da Vinci procedure growth slowed to 10% in Q3.
Slightly Bullish +20
A $5.9 Billion Fund Is Betting Big on Intuitive Surgical
AI-generated analysis
Key insights
๐ Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
๐ Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
๐ฐ The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
โ๏ธ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
๐ Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
๐ The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
๐ผ GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
๐ญ Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
๐ The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
๐ Bullish signals
๐Intuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
๐ฐThe company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
๐ญAnalysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
๐ Risk factors
๐U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
โ๏ธThe company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
๐Valuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Article
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Intuitive Surgical (ISRG) stock is currently trading at $393.33, presenting a technical setup where buyers could see a potential 23.9% rally to the April high of $487.45, though historical price action over the last two years suggests caution as no prior entry in this range resulted in a 20% gain before a 5% drop.
Fundamental concerns weigh on the stock, specifically a slowdown in US da Vinci procedure growth which decelerated to 12% in the second quarter of 2026 from 14% in the first. Management attributes this partly to patients delaying elective procedures due to coverage changes and the law of large numbers, while competitors' pricing strategies via extended use programs threaten to lower revenue per procedure.
Despite these headwinds, ISRG maintains strong operational momentum with hospitals continuing to purchase systems; the company placed 468 da Vinci units in Q2 2026, an 18% increase year-over-year. Revenue growth remains robust at 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%, though the stock trades at a premium valuation of 44.4 times earnings compared to the index median of 22.4.
๐ ISRG faces potential 23.9% upside rally to $487.45 if clearing resistance.
โ ๏ธ Past data shows ISRG failed to gain 20% in this range before dropping 5%.
๐ US da Vinci procedure growth slowed to 12% due to insurance coverage changes.
๐ฐ ISRG placed 468 da Vinci systems in Q2 2026, an 18% year-over-year increase.
๐ ISRG revenue grew 20.7% over last twelve months, beating S&P 500 median.
๐ ISRG stock faces a potential 23.9% upside rally to $487.45 if it clears technical resistance at $429.72 and $452.35.
โ ๏ธ Historical data shows that over the last two years, every time ISRG entered this price range, it failed to generate a 20% gain before dropping 5%.
๐ US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, driven by patients delaying elective care due to insurance coverage changes.
๐ฐ ISRG placed 468 da Vinci systems in the second quarter of 2026, representing an 18% increase compared to the same period last year.
๐ Revenue grew 20.7% over the last twelve months, significantly exceeding the S&P 500 median growth rate of 8.3%.
๐ธ An extended use program introduced in H1 2027 allows instruments to be used more times, potentially lowering the price per procedure for benign surgeries.
๐ The stock trades at 44.4 times earnings, a premium valuation that is vulnerable if lower pricing per procedure materializes.
๐ Management expects deferred medical conditions will eventually progress and require treatment, supporting long-term demand despite current delays.
Bullish Signals
Placed 468 da Vinci systems in Q2 2026, up 18% YoY.
Revenue grew 20.7% over last twelve months vs S&P 500 median of 8.3%.
Shift to da Vinci 5 systems accretive to revenue per procedure.
Risk Factors
US da Vinci procedure growth slowed to 12% in Q2 2026.
Insurance coverage changes affect patient care timing.
Extended use program may lower benign surgery prices.
Valuation at 44.4x earnings is double S&P 500 median.
Bullish Signals
ISRG placed 468 da Vinci systems in Q2 2026, an 18% year-over-year increase in hospital placements.
Revenue grew 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%.
The shift toward da Vinci 5 systems has been accretive to revenue per procedure.
Risk Factors
US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, indicating a slowdown in elective procedures.
Customers report that insurance coverage changes are affecting when patients seek care for treatable conditions.
An extended use program starting in H1 2027 may lower the price per procedure for benign surgeries, potentially denting margins.
The stock trades at 44.4 times earnings, a valuation more than double the S&P 500 median of 22.4x, making it sensitive to growth disappointments.
Intuitive Surgical (ISRG) shares rose approximately 1% in after-hours trading following the release of quarterly financial results that exceeded market expectations. The medical robotics provider reported an adjusted earnings per share of $1.50, surpassing analyst estimates of $1.41, while revenue reached $1.89 billion, slightly beating the consensus forecast.
The company's positive performance was driven by stronger-than-anticipated operational metrics across its robotic-assisted surgical solutions portfolio. This beat in both top-line revenue and bottom-line earnings suggests robust demand for its core products despite broader market volatility observed in other sectors during the extended trading session.
๐ ISRG shares gained 1% after-hours following earnings beat.
๐ฐ Adjusted EPS of $1.50 exceeded analyst estimates of $1.41.
Intuitive Surgical (ISRG) shares edged higher on September 17, 2026, closing at USD 383.54 on the Nasdaq following a significant regulatory milestone and strong quarterly performance. The company received CE mark approval in Europe for its da Vinci SP single-port robotic system to perform transvaginal gynecologic procedures, expanding its approved indications and deepening its presence in minimally invasive women's health markets.
Fundamental growth remains robust despite a broader stock correction of 32.3% year-to-date in 2026. The second quarter of 2026 delivered year-on-year increases in both revenue and da Vinci procedure volume, validating the company's expansion strategy. Additionally, Intuitive Surgical highlighted continued growth in installed systems and recurring revenue from instruments and accessories, reinforcing the durability of its razor-and-blades business model.
Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of USD 508.68, implying approximately 32.6% upside from current levels. While Vice President Fredrik Widman executed a planned Rule 10b5-1 sale of shares worth roughly USD 407,765, institutional investors maintain a dominant 83.6% ownership stake, signaling strong professional confidence in the company's long-term trajectory and valuation entry point.
๐ ISRG stock closed at USD 383.54 on Sept 17, 2026, gaining 0.33% on EU approval for da Vinci SP.
โ CE mark now covers transvaginal gynecologic procedures, expanding da Vinci SP indications in Europe.
๐ Q2 2026 revenue and procedure volume grew year-over-year, strengthening the razor-and-blades ecosystem.
๐ Shares declined 32.3% YTD from USD 566.36 high despite operational growth momentum.
๐ Intuitive Surgical stock closed at USD 383.54 on September 17, 2026, gaining 0.33% as investors reacted to new EU approval for the da Vinci SP system.
โ The European CE mark now covers transvaginal gynecologic procedures for the da Vinci SP, expanding the platform's approved indications in the region.
๐ Q2 2026 fundamentals showed year-on-year growth in revenue and da Vinci procedure volume, underscoring continued business expansion.
๐ฐ Recurring revenue from instruments and accessories grew in Q2 2026, strengthening the company's razor-and-blades ecosystem model.
๐ฏ Analysts maintain a Moderate Buy rating with an average price target of USD 508.68, suggesting roughly 32.6% upside potential.
๐ Shares have declined 32.3% year-to-date in 2026 from a high of USD 566.36, creating a valuation contrast with operational growth.
๐ Vice President Fredrik Widman sold 1,089 shares under a Rule 10b5-1 plan for approximately USD 407,765 on September 17.
๐ฆ Institutional investors hold roughly 83.6% of Intuitive Surgical's outstanding shares, indicating strong professional ownership.
๐ฌ The company continues to expand its installed base of da Vinci systems while maintaining momentum in robotic procedures.
Bullish Signals
da Vinci SP got CE mark for transvaginal procedures in Europe.
Risk Factors
Shares fell 32.3% YTD in 2026 below analyst valuations.
VP sold 1,089 shares worth USD 407,765 on Sept 17, 2026.
Bullish Signals
Intuitive Surgical received CE mark approval in Europe for the da Vinci SP system to perform transvaginal gynecologic procedures, expanding its market presence.
Q2 2026 revenue and da Vinci procedure volume both increased year-on-year, demonstrating sustained business momentum despite stock price corrections.
The company reported continued growth in installed da Vinci systems and recurring revenue from instruments and accessories in Q2 2026.
Analyst consensus rates the stock as a Moderate Buy with an average price target of USD 508.68, implying approximately 32.6% upside from current levels.
Institutional investors maintain a dominant 83.6% ownership stake in Intuitive Surgical shares, reflecting strong professional confidence.
Risk Factors
Intuitive Surgical shares have fallen by 32.3% year-to-date in 2026 from a starting level of USD 566.36, trading below typical analyst valuation benchmarks.
Vice President Fredrik Widman sold 1,089 shares worth approximately USD 407,765 under a Rule 10b5-1 plan on September 17, 2026.
Intuitive Surgical (ISRG) is being re-evaluated as a compelling long-term investment, though the analyst notes that current valuation levels require strong execution to justify the price. The company's Q2 financial performance showed revenue growth moderating to 18.5%, while operating income surged by 30.7% and margins expanded even after adjusting for tariff refunds.
The business model is driven significantly by recurring revenue from instruments, services, and leases, which accounted for 86% of incremental sales. This recurring nature is supported by strong system adoption and installed base growth, which in turn support future procedure volumes. The analyst concludes that while lower multiples offer a better risk-return balance, the stock has been upgraded to a Hold rating.
The upgrade reflects a shift from a previous bullish stance taken in June, where the analyst liked the company's hospital relationships and surgical platform but was concerned about the price. The current view suggests that while procedure growth and demand require close monitoring, the resilient earnings and lower multiples present an improved opportunity compared to the higher valuation previously observed.
๐ ISRG upgraded to Hold as lower multiples improve risk-return balance.
๐ฐ Q2 revenue grew 18.5% while operating income surged 30.7%.
๐ Recurring revenue from instruments and services drove 86% of sales.
๐ฅ Strong installed base growth supports future procedure volumes and demand.
โ๏ธ Current valuation requires strong execution to justify the price.
๐ Intuitive Surgical (ISRG) is upgraded to a Hold rating as the sell case loses ground due to lower multiples and resilient earnings offering better risk-return balance.
๐ฐ Q2 revenue growth moderated to 18.5%, while operating income surged 30.7% with expanded margins even after adjusting for tariff refunds.
๐ Recurring revenue from instruments, services, and leases drove 86% of incremental sales, highlighting the strength of the installed base.
๐ฅ Strong system adoption and installed base growth continue to support future procedure volumes and long-term demand.
โ๏ธ The analyst previously held a bullish view in June but now emphasizes that current valuation demands strong execution to justify the price.
Bullish Signals
Operating income surged 30.7% in Q2.
Margins expanded despite tariff refunds.
Recurring revenue drove 86% of sales.
Installed base growth supports future demand.
Risk Factors
Revenue growth slowed to 18.5%.
Valuation remains high despite execution risks.
Bullish Signals
Operating income surged 30.7% in Q2, demonstrating resilient earnings despite moderate revenue growth.
Margins expanded during the quarter even after adjusting for tariff refunds, indicating operational efficiency.
Recurring revenue from instruments, services, and leases drove 86% of incremental sales, providing stable cash flow.
System adoption and installed base growth are supporting future procedure volumes, ensuring long-term demand.
Risk Factors
Revenue growth moderated to 18.5%, indicating a slowdown in top-line expansion compared to previous periods.
Current valuation levels are considered high, requiring strong execution to justify the price for investors.
Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius sold 46 shares of the company's stock on September 8th under a pre-arranged Rule 10b5-1 trading plan. The transaction, valued at $16,616.58, reduced his personal holding by 5.22%, leaving him with 835 shares worth approximately $301,627. This insider sale is a routine disclosure event and does not necessarily indicate a change in the company's long-term outlook.
The medical technology firm recently reported strong quarterly financial results released on July 16th. Intuitive Surgical generated revenue of $2.89 billion, surpassing analyst consensus estimates of $2.83 billion, while posting earnings per share (EPS) of $2.80 against an expected $2.48. The company's revenue grew by 18.4% year-over-year, driven by its da Vinci Surgical System used across various surgical specialties.
Analyst sentiment remains mixed but generally positive regarding the stock's valuation and growth trajectory. While Royal Bank of Canada lowered its price target to $600 and Bank of America reduced theirs to $515, major institutions like KeyCorp and Piper Sandler maintain 'overweight' or 'outperform' ratings. Institutional ownership stands at 83.64%, with several hedge funds increasing their stakes in the fourth quarter.
๐ EVP Mark Brosius sold 46 shares under Rule 10b5-1 plan.
๐ฐ Q2 revenue hit $2.89B, beating estimates by $0.06B.
๐ EPS reached $2.80, significantly exceeding analyst expectations of $2.48.
๐ Revenue grew 18.4% YoY driven by da Vinci system demand.
๐ Stock trades at 40.46 P/E with $508.68 average price target.
๐ EVP Mark Brosius sold 46 shares of ISRG for $16,616.58 on September 8th under a pre-arranged Rule 10b5-1 trading plan.
๐ฐ The company reported Q2 revenue of $2.89 billion, beating the consensus estimate of $2.83 billion by $0.06 billion.
๐ Intuitive Surgical posted EPS of $2.80 for the quarter, significantly exceeding analyst expectations of $2.48.
๐ Revenue grew 18.4% year-over-year, demonstrating continued strong demand for the da Vinci Surgical System.
๐ฆ The stock trades at a P/E ratio of 40.46 with a market capitalization of $124.79 billion.
๐ Analyst consensus rating is 'Moderate Buy' with an average price target of $508.68.
Bullish Signals
Revenue beat estimates at $2.89 billion.
EPS of $2.80 exceeded consensus of $2.48.
Revenue grew 18.4% year-over-year.
Analysts maintain 'overweight' ratings on stock.
Hedge funds increased stakes significantly.
Risk Factors
RBC cut price target from $650 to $600 due to conservative valuation.
BofA lowered price target from $520 to $515 adjusting near-term expectations.
Bullish Signals
Intuitive Surgical beat quarterly revenue estimates by $0.06 billion, reporting $2.89 billion in revenue.
The company significantly exceeded earnings expectations with EPS of $2.80 versus the consensus of $2.48.
Revenue grew 18.4% year-over-year, indicating robust market expansion for its robotic surgical systems.
KeyCorp and Piper Sandler maintain 'overweight' ratings on the stock, signaling confidence in its long-term prospects.
High Note Wealth LLC increased its position by 50%, while other hedge funds like Prosperity Consulting Group boosted stakes.
Risk Factors
Royal Bank of Canada lowered its price target from $650 to $600, citing a more conservative valuation outlook.
Bank of America decreased its price target from $520 to $515, reflecting a slight adjustment in near-term expectations.
Intuitive Surgical (ISRG) is trading at a forward 12-month P/E of 30.26X, significantly below its 10-year median of 58.18X and historical high of 93.22X, marking its cheapest valuation in a decade following a price decline exceeding 40%. Despite the steep multiple compression, the company maintains a 'D' Value Score, indicating it is not yet considered an outright bargain relative to the broader medical instruments industry average of 25.96X.
Fundamental performance remains robust with second-quarter 2026 revenue rising 19% year-over-year to $2.89 billion and adjusted EPS advancing 28%. Total procedures increased 16%, driven by a 15% rise in da Vinci systems and a 36% surge in Ion procedures. Recurring revenue climbed to $2.47 billion, representing 85% of total revenue, while system utilization improved across both platforms.
Management maintains its 2026 guidance for da Vinci procedure growth between 13.5% and 15.5%, citing international expansion as a key driver with 20% growth in Europe and Asia. However, the outlook incorporates near-term uncertainties including potential impacts from U.S. patient behavior changes, competitive pressures in China, European capital constraints, and the broader effects of obesity drug adoption on surgical volumes.
While ISRG faces headwinds such as higher freight costs, semiconductor expenses, and elevated depreciation during platform transitions, its strong product pipeline offers a counterweight to concerns. The company has installed over 1,700 da Vinci 5 systems and is rapidly gaining traction with single-port procedures, which grew 61% in the quarter. Analysts suggest holding for existing investors while prospective buyers may wait for further evidence of accelerating growth before committing aggressively.
๐ Stock down 40% from peak, trading at 30.26X forward P/E.
๐ฐ Q2 revenue up 19% to $2.89B with EPS rising 28%.
๐ง Procedures rose 16%; Ion procedures jumped 36% to 48,000.
โ ๏ธ U.S. growth faces headwinds from ACA subsidies and obesity drugs.
๐จ๐ณ China expansion challenged by competition and tender volume issues.
๐ ISRG stock has declined over 40% from its January peak, trading at a forward P/E of 30.26X versus a 10-year median of 58.18X.
๐ฐ Second-quarter 2026 revenue increased 19% year-over-year to $2.89 billion with adjusted EPS advancing 28%.
๐ง Total procedures rose 16%, with da Vinci procedures up 15% and Ion procedures jumping 36% to 48,000.
๐ Recurring revenue climbed 19% to $2.47 billion, now representing 85% of total revenue base.
๐ International da Vinci procedures grew 20% in the quarter, with Europe and Asia each advancing 20%.
โ ๏ธ Management forecasts U.S. procedure growth moderation due to ACA subsidy changes and obesity drug impacts.
๐จ๐ณ China faces competitive pressure and tender volume challenges affecting near-term international expansion.
๐ธ Gross margin outlook raised to 68-69% but elevated spending on freight, semiconductors, and depreciation expected.
๐ค Over 1,700 da Vinci 5 systems are installed with more than 100 planned updates rolling out globally.
๐ Single-port procedures increased 61% as the global installed base reached 445 systems.
๐ฅ ISRG lags the broader medical sector and its own industry peers over the past three months.
๐ฌ The company is progressing with ROSE and EBUS programs and submitted a next-gen flexible endoscope for FDA clearance.
Bullish Signals
Trades at forward P/E of 30.26X vs 10-year median of 58.18X.
Q2 2026 revenue rose 19% YoY to $2.89B with EPS up 28%.
Ion procedures jumped 36% in the quarter, surpassing 400,000 cumulatively.
International da Vinci procedures grew 20%, with Europe and Asia each advancing 20%.
Recurring revenue climbed 19% to $2.47B, representing a resilient 85% of total.
Risk Factors
China competition moderates U.S. procedure trends affecting growth.
Higher freight and chip costs pressure profitability margins.
Intuitive Surgical (ISRG) shares closed on September 4, 2026, at USD 366.70 on the Nasdaq, marking a 2.9% decline from the prior session. The stock finished significantly below its recent peak, trading approximately 39% under its 52-week high of roughly USD 603.88 and down about 21.5% over the past twelve months.
Despite the recent price weakness, market data indicates that Intuitive Surgical trades at a discount relative to analyst consensus, with an average price target near USD 508.68. The company maintains a substantial market capitalization of approximately USD 131.38 billion, reflecting its status as a major player in the medical technology sector.
Trading volume for the session remained consistent with recent patterns, though Intuitive Surgical underperformed the broader Nasdaq Composite index and the wider healthcare cohort. With no company-specific earnings reports or scheduled events imminent, near-term stock movements are expected to be driven primarily by broader market dynamics, sector performance, and macroeconomic indicators rather than specific corporate developments.
๐ ISRG stock closed down 2.9% at USD 366.70 on September 4, 2026.
๐ Shares trade 39% below the 52-week high of USD 603.88.
๐ The stock has declined roughly 21.5% over the past twelve months.
๐ฐ ISRG maintains a market capitalization of around USD 131.38 billion.
๐ฏ Analyst consensus suggests an average price target near USD 508.68.
๐ Intuitive Surgical stock closed down 2.9% at USD 366.70 on September 4, 2026.
๐ Shares are trading approximately 39% below their 52-week high of USD 603.88.
๐ The stock has declined roughly 21.5% over the past twelve months.
๐ฐ Intuitive Surgical maintains a market capitalization of around USD 131.38 billion.
๐ฏ Analyst consensus suggests an average price target near USD 508.68, indicating the current price is below expectations.
๐ The company underperformed the broader Nasdaq Composite and healthcare indices during the session.
๐ No earnings reports or major corporate events are scheduled for the immediate future.
Bullish Signals
Intuitive Surgical trades at a discount relative to analyst consensus, with an average price target near USD 508.68 suggesting potential upside from current levels.
The company maintains a robust market capitalization of approximately USD 131.38 billion, indicating strong overall market valuation despite recent short-term declines.
Risk Factors
Intuitive Surgical shares closed down 2.9% and are trading roughly 39% below their 52-week high.
The stock has experienced a significant drawdown of approximately 21.5% over the past twelve months.
Intuitive Surgical underperformed the broader Nasdaq Composite index and the wider healthcare sector during the trading session.
Intuitive Surgical (ISRG), a pioneer in surgical robotics, is experiencing a significant growth slowdown following post-pandemic highs. The company's market share faces increasing pressure as medical device giants like Medtronic and Johnson & Johnson enter the competitive landscape with their own robotic systems, creating material competition for Intuitive's core da Vinci platform.
Despite the competitive headwinds, Intuitive Surgical maintains a robust financial foundation driven by its service business. Approximately 75% of the company's top line now comes from maintenance and servicing contracts for existing da Vinci systems, providing a steady annuity-like revenue stream that persists as long as these surgical robots remain in clinical use.
Management views future growth through continued technological advancements, specifically focusing on integrating artificial intelligence into robotic surgery applications. Historically, the company has demonstrated resilience by recovering from previous drawdowns to achieve higher highs, leading analysts to characterize the current stock sell-off as a potential buying opportunity for investors.
๐ Growth slowed due to increased competition in surgical robotics.
๐ฅ Medtronic and Johnson & Johnson now challenge market dominance.
๐ฐ 75% revenue comes from da Vinci system maintenance contracts.
๐ Service model provides steady annuity-like income stream.
๐ค AI advances drive future growth opportunities for robotic surgery.
๐ Intuitive Surgical's growth has slowed significantly since post-pandemic peaks due to increased competition in the surgical robotics market.
๐ฅ Major medical device competitors including Medtronic and Johnson & Johnson are now entering the fray, challenging Intuitive Surgical's dominance.
๐ฐ Approximately 75% of Intuitive Surgical's revenue is derived from maintenance and servicing contracts for existing da Vinci systems.
๐ This service-based business model provides a steady annuity-like income stream that continues as long as da Vinci systems are in use.
๐ค The company is pursuing growth opportunities through technological advances, particularly in the application of artificial intelligence to robotic surgery.
๐ Historical performance suggests Intuitive Surgical has recovered from previous drawdowns to reach higher highs, indicating resilience.
Bullish Signals
Intuitive Surgical generates a steady annuity-like revenue stream where approximately 75% of its top line comes from maintenance and servicing of existing da Vinci systems.
The company has a historical track record of recovering from previous drawdowns and achieving higher highs, suggesting resilience in the face of market volatility.
Risk Factors
Intuitive Surgical's growth has slowed significantly since post-pandemic highs due to material competition entering the surgical robotics market.
The competitive landscape is intensifying as medical device giants like Medtronic and Johnson & Johnson launch their own robotic systems, challenging Intuitive Surgical's market position.
Intuitive Surgical (ISRG) remains the undisputed leader in robotic-assisted surgery, trading at a premium valuation of 42.5 times earnings compared to peers like Medtronic at 24.2x. Despite commanding the highest operating margin in its peer group at 31% and delivering robust revenue growth of 21% over the last twelve months, the stock has underperformed significantly with a -21% return over the past year, trailing the S&P 500's gains.
The company's high valuation is driven by a strong upgrade cycle for its da Vinci 5 system, evidenced by placing 468 systems in the second quarter, with nearly half being the newer model. International expansion continues to provide crucial growth support, with procedure volume increasing 20% outside the U.S., offsetting signs of maturation in the domestic market where patient insurance changes are affecting deferrable procedures.
Investors are closely watching whether ISRG can meet its full-year guidance for worldwide da Vinci procedure growth between 13.5% and 15.5%. Management has affirmed this target, suggesting that if achieved, it would validate the bull case that the U.S. slowdown is manageable. The core metric driving recurring revenue remains the number of procedures performed, making adherence to these targets critical for sustaining its premium market capitalization.
๐ ISRG trades at 42.5x earnings vs Medtronic's 24.2x despite underperformance.
๐ฐ Achieved 31% operating margin, outperforming industry and rival Medtronic.
๐ Revenue grew 21% with 468 da Vinci systems placed in Q2.
โ ๏ธ U.S. procedure growth moderated due to patient insurance coverage changes.
๐ International procedure volume expanded 20% outside the U.S.
๐ ISRG trades at a premium 42.5x earnings multiple compared to peer Medtronic's 24.2x despite recent stock underperformance.
๐ฐ The company achieved a leading 31% operating margin, significantly outperforming the industry average and rival Medtronic's 18.8%.
๐ Revenue grew 21% over the last twelve months, demonstrating superior execution against diversified competitors like Medtronic.
๐ง A healthy upgrade cycle is underway with 468 da Vinci systems placed in Q2, including 246 units of the new da Vinci 5 model.
๐ International growth remains robust with procedure volume expanding 20% outside the U.S. to offset domestic market saturation.
โ ๏ธ U.S. procedure growth has moderated due to changes in patient insurance coverage affecting deferrable surgical procedures.
๐ฏ Management reaffirmed a full-year guidance range for worldwide da Vinci procedure growth between 13.5% and 15.5%.
๐ The stock delivered a -21% return over the last twelve months, badly trailing the S&P 500's +19.2% gain.
Bullish Signals
ISRG commands the highest operating margin in its peer group at 31%, significantly outperforming rivals like Medtronic.
Revenue grew 21% over the last twelve months, demonstrating superior operational execution compared to diversified competitors.
The company is executing a powerful upgrade cycle with strong capital equipment sales, placing 468 da Vinci systems in Q2 alone.
International expansion provides a crucial growth offset with procedure volume growing 20% outside the U.S. market.
Risk Factors
The stock has delivered a -21% return over the last twelve months, significantly underperforming the S&P 500's +19.2% gain.
Growth in the U.S. market is moderating due to changes in patient insurance coverage affecting deferrable procedures.
Intuitive Surgical (ISRG) EVP Mark Brosius sold 77 shares of the company's stock on August 17th for a total value of $30,081.59 at an average price of $390.67 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a 6.08% decrease in his direct ownership, leaving him with 1,189 shares valued at approximately $464,506. This insider sale is a routine disclosure filed with the SEC.
The company recently reported strong quarterly financial performance, beating analyst expectations for both earnings per share and revenue. Intuitive Surgical posted EPS of $2.80 compared to a consensus of $2.48, while revenue reached $2.89 billion against expectations of $2.83 billion. Year-over-year revenue growth was 18.4%, driven by the company's core robotic-assisted surgical systems and related technologies.
Institutional investors have significantly increased their stakes in Intuitive Surgical over the past few quarters, with major entities like Norges Bank, Bank of New York Mellon, and J. Stern & Co. adding substantial positions. Hedge funds and wealth management firms collectively hold a large portion of the float, indicating strong institutional confidence despite mixed analyst price targets ranging from $500 to $590.
๐ ISRG EVP Mark Brosius sold 77 shares for $30,081.59 under Rule 10b5-1 plan.
๐ฐ Q2 EPS hit $2.80, beating consensus by $0.32.
๐ Revenue reached $2.89 billion, up 18.4% year-over-year.
๐ฆ Norges Bank acquired new stake worth $2.86 billion in Q4.
๐ Institutional ownership stands at 83.64% with recent additions.
๐ ISRG EVP Mark Brosius sold 77 shares for $30,081.59 under a pre-arranged Rule 10b5-1 trading plan on August 17th.
๐ฐ The company reported Q2 EPS of $2.80, beating the consensus estimate of $2.48 by $0.32.
๐ ISRG revenue reached $2.89 billion for the quarter, exceeding analyst expectations of $2.83 billion.
๐ Revenue grew 18.4% year-over-year, demonstrating continued strong demand for robotic surgical systems.
๐ฆ Norges Bank acquired a new stake worth approximately $2.86 billion in the fourth quarter.
๐ Institutional ownership stands at 83.64%, with significant additions from J. Stern & Co. and Northwestern Mutual.
๐ฏ Analyst consensus rating is 'Moderate Buy' with a target price of $508.68 according to MarketBeat.
๐ Bank of America lowered its price target from $520 to $515 in a recent research report.
๐ Sanford C. Bernstein reaffirmed an 'outperform' rating on ISRG shares in August.
๐ป The company maintains a market cap of $140.51 billion with a PE ratio of 45.56.
Bullish Signals
EPS beat at $2.80 vs $2.48 consensus.
Revenue hit $2.89B, beating $2.83B estimates.
Revenue grew 18.4% year-over-year in robotics.
Norges Bank added $2.86B stake in Q4.
Oppenheimer upgraded to 'outperform' with $500 target.
Risk Factors
Bank of America cut price target from $520 to $515.
Mizuho assigned neutral rating with $500 price target.
Citigroup lowered price target from $590 to $500.
High PE ratio of 45.56 limits upside if growth slows.
Bullish Signals
Intuitive Surgical beat Q2 earnings estimates with EPS of $2.80 versus the consensus of $2.48.
The company reported revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion.
Revenue increased 18.4% year-over-year, highlighting strong growth in its robotic surgical systems business.
Norges Bank added a new stake worth $2.86 billion to its holdings in the fourth quarter.
J. Stern & Co. LLP grew its stake by 18,504.6% in the fourth quarter, adding over 2 million shares.
Arrowstreet Capital Limited Partnership lifted its stake by 95.3% in the first quarter.
Sanford C. Bernstein reaffirmed an 'outperform' rating on ISRG shares in a recent research note.
Oppenheimer upgraded its rating to 'outperform' and set a $500 price objective for the stock.
Risk Factors
Bank of America dropped its price target from $520.00 to $515.00 in a research report.
Mizuho assigned a 'neutral' rating and set a $500.00 price target on ISRG shares.
Citigroup reduced its price target from $590.00 to $500.00, though it maintained a 'buy' rating.
The stock trades at a high PE ratio of 45.56, which may limit upside potential if growth slows.
Intuitive Surgical (ISRG) is a leader in robotic-assisted surgery with a market capitalization of $125.08 billion as of July 20, 2026. Despite releasing solid quarterly results where revenue and Da Vinci procedure growth topped consensus estimates, the stock faced headwinds from disappointing system placements in China and Japan. The company recently repurchased 2.3 million shares for $1.1 billion in the first quarter of 2026, signaling management's confidence in its long-term value despite near-term volatility.
TCW Concentrated Large Cap Growth Fund maintains a constructive stance on ISRG, highlighting the company's 20-year lead over competitors and its strong competitive moat in minimally invasive care. The fund notes that while shares have been challenged year-to-date due to negative sentiment in healthcare medtech stocks and high valuation multiples, management has raised 2026 guidance. The firm remains optimistic about the upcoming launch of the Da Vinci 5 system, which is expected to drive further penetration into new hospitals and procedure categories.
Although TCW acknowledges ISRG's potential, it currently views AI-focused stocks as offering greater promise for higher returns within a shorter timeframe compared to Intuitive Surgical. Hedge fund holdings in the company decreased slightly from 109 portfolios in the previous quarter to 103 at the end of the first quarter. The article concludes that while ISRG is not on TCW's list of most popular stocks heading into 2026, the investment firm remains constructive on its long-term prospects.
๐ ISRG revenue and Da Vinci procedure growth beat consensus estimates.
๐ Shares fell on healthcare medtech sentiment despite strong fundamentals.
๐ System placements disappointed specifically in China and Japan markets.
๐ฐ ISRG repurchased 2.3 million shares worth $1.1 billion in Q1 2026.
๐ Management raised 2026 guidance citing confidence in future growth.
๐ Intuitive Surgical (ISRG) reported solid quarterly results with revenue and Da Vinci procedure growth exceeding consensus estimates.
๐ Shares of ISRG moved lower despite strong fundamentals due to negative investor sentiment in healthcare medtech and high valuation multiples.
๐ System placements for ISRG continue to disappoint specifically in the China and Japan markets.
๐ฐ ISRG repurchased 2.3 million shares worth $1.1 billion during the first quarter of 2026.
Johnson & Johnson (JNJ) has received FDA De Novo authorization for its OTTAVA robotic surgical system, officially entering the U.S. soft-tissue market where Intuitive Surgical (ISRG) currently dominates. The OTTAVA platform features a unique table-integrated architecture that occupies 30% to 50% less space than traditional boom-mounted systems, potentially appealing to hospitals with limited operating room capacity. This strategic move aims to convert J&J's existing surgical portfolio and relationships into meaningful market share against the established leader.
Intuitive Surgical maintains a formidable competitive position with an installed base of 11,710 da Vinci systems as of Q2 2026, up 12% year-over-year. The company reported strong financial performance in fiscal Q2, with revenue rising 19% to $2.89 billion and instruments/accessories revenue increasing 18% to $1.73 billion. Despite the new entrant, Intuitive's procedure volume grew approximately 16%, indicating that hospitals continue adopting newer platforms like the da Vinci 5 even as competition intensifies.
J&J plans a selective commercial launch in the U.S. with select customers to focus on early success and gather real-world feedback before broader expansion. While the OTTAVA system is unlikely to materially impact J&J's near-term financial results given the limited rollout, successful adoption could eventually strengthen its MedTech business, which generated $8.93 billion in Q2 2026 sales. Investors will closely monitor the pace of placements and indication expansion, particularly in urology, to determine if OTTAVA can truly challenge Intuitive's leadership.
Analysts suggest that while OTTAVA represents a credible platform with differentiated design, Intuitive Surgical remains difficult to displace due to its entrenched ecosystem of recurring revenue from instruments and services. The article concludes that the FDA authorization marks the beginning of a commercial challenge rather than an immediate threat to Intuitive's market dominance, though J&J's broader portfolio offers potential synergies for future growth.
๐ FDA authorizes J&J OTTAVA robotic system for U.S. soft-tissue market.
๐ง OTTAVA table-integrated design saves 30% to 50% space vs boom systems.
๐ฅ System approved for gastric bypass, gastrectomy, and cholecystectomy procedures.
๐ J&J launches OTTAVA selectively with select U.S. customers for training.
โ๏ธ Analysts see urology authorization as key to competing with Intuitive Surgical.
๐ Johnson & Johnson received FDA De Novo authorization for its OTTAVA robotic surgical system, entering the U.S. soft-tissue market.
๐ง OTTAVA features a table-integrated design occupying 30% to 50% less space than traditional boom-mounted systems.
๐ฅ The system is authorized for multiple upper-abdominal procedures including gastric bypass, gastrectomy, and cholecystectomy.
๐ J&J will launch OTTAVA selectively with select U.S. customers to focus on early customer success and training.
๐ Intuitive Surgical reported 11,710 installed da Vinci systems at the end of Q2 2026, up 12% from the previous year.
๐ฐ Intuitive Surgical revenue rose 19% to $2.89 billion in fiscal Q2, with instruments/accessories revenue up 18% to $1.73 billion.
๐ Worldwide da Vinci and Ion procedure volume grew approximately 16% for Intuitive Surgical in the second quarter.
๐ฌ J&J is conducting an ongoing U.S. clinical trial for OTTAVA in inguinal hernia procedures.
โ๏ธ Analysts view urology authorization as a key differentiator necessary for more direct competition with Intuitive Surgical.
๐ก๏ธ Intuitive Surgical's recurring revenue model from instruments and services creates a strong barrier to entry for new competitors.
Bullish Signals
FDA authorized OTTAVA for multiple upper-abdominal procedures.
OTTAVA occupies 30% to 50% less space than traditional systems.
Revenue rose 19% to $2.89 billion in fiscal Q2 2026.
468 da Vinci systems placed, including 246 da Vinci 5 units.
MedTech segment generated $8.93 billion in second-quarter 2026 sales.
Risk Factors
OTTAVA unlikely to affect J&J near-term results due to limited launch.
Intuitive Surgical has 11,710 da Vinci systems generating recurring revenue.
Hospital adoption of OTTAVA remains unproven requiring extensive training.
Competition has not yet disrupted Intuitive Surgical's growth trajectory.
Urology authorization necessary for OTTAVA to challenge Intuitive Surgical.
Bullish Signals
Johnson & Johnson has secured FDA De Novo authorization for the OTTAVA robotic surgical system, validating its technology for multiple upper-abdominal procedures.
OTTAVA's table-integrated architecture offers a unique value proposition by occupying 30% to 50% less space than traditional systems, appealing to hospitals with capacity constraints.
Intuitive Surgical demonstrated robust growth with revenue rising 19% to $2.89 billion and procedure volume increasing 16% in fiscal Q2 2026.
Intuitive Surgical placed 468 da Vinci systems in the quarter, including 246 units of the newer da Vinci 5 platform, showing strong market adoption.
J&J's MedTech segment generated $8.93 billion in second-quarter 2026 sales, providing a solid financial foundation for future robotic surgery investments.
Intuitive Surgical's instruments and accessories revenue increased 18% to $1.73 billion, highlighting the strength of its recurring revenue ecosystem.
Risk Factors
OTTAVA is unlikely to materially affect Johnson & Johnson's near-term financial results due to a limited selective launch strategy.
Intuitive Surgical holds a significant competitive advantage with an installed base of 11,710 da Vinci systems that generate recurring revenue from instruments and services.
Hospital adoption of OTTAVA remains unproven as the system requires extensive training, workflow integration, and sufficient procedure volumes to justify investment.
Competition has not yet disrupted Intuitive Surgical's growth trajectory, suggesting its ecosystem remains resilient despite new entrants like J&J.
Urology authorization is viewed by analysts as a necessary condition for OTTAVA to mount a more direct challenge to Intuitive Surgical's dominance.
Intuitive Surgical Director Amy Ladd sold 72 shares of the company's stock on August 11th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $393.10 per share, totaling approximately $28,303, leaving her with 179 shares valued at roughly $70,365. This sale represents a 28.69% decrease in her personal ownership stake.
The medical technology company recently reported strong quarterly financial results released on July 16th. Intuitive Surgical achieved revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion, and posted earnings per share of $2.80 against a consensus estimate of $2.48. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%.
Institutional investor activity shows mixed signals alongside recent analyst adjustments. Several hedge funds, including Brighton Jones LLC and Main Street Financial Solutions LLC, significantly increased their stakes in the second quarter. However, major analysts like Stifel Nicolaus and BTIG Research lowered their price targets to $550 and $469 respectively, though the consensus rating remains a 'Moderate Buy' with a target price of $509.02.
๐ฐ Q2 revenue hit $2.89B, beating estimates by $60M.
๐ EPS reached $2.80, topping the consensus of $2.48.
๐ฆ Institutional ownership stands at 83.64% with increased holdings.
๐ Stifel lowered price target to $550 while keeping 'buy'.
๐ญ Full-year EPS forecast is $8.87 for current fiscal year.
๐ Director Amy Ladd sold 72 shares for $28,303 under a pre-arranged Rule 10b5-1 trading plan on August 11th.
๐ฐ The company reported Q2 revenue of $2.89 billion, beating estimates by $60 million and growing 18.4% year-over-year.
๐ Intuitive Surgical posted earnings per share of $2.80, significantly topping the consensus estimate of $2.48.
๐ฆ Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing holdings by 24.9% in Q4.
๐ Analyst Stifel Nicolaus lowered its price target from $670 to $550 while maintaining a 'buy' rating.
๐ BTIG Research reduced its price objective from $512 to $469, citing a 'buy' recommendation.
๐ The stock trades at a P/E ratio of 45.96 with a market capitalization of $141.75 billion.
๐ญ Analysts forecast full-year earnings per share of $8.87 for the current fiscal year.
๐ฅ Intuitive Surgical's core business focuses on da Vinci robotic-assisted surgical systems and related instruments.
๐ Royal Bank Of Canada reduced its price target to $600 but maintained an 'outperform' rating.
Director Amy Ladd sold holdings (28.69% decrease).
Stifel lowered price target from $670 to $550.
BTIG reduced objective from $512 to $469.
Royal Bank of Canada cut target from $650 to $600.
Bullish Signals
Revenue of $2.89 billion exceeded analyst expectations of $2.83 billion, demonstrating strong market demand.
Earnings per share of $2.80 beat the consensus estimate of $2.48 by $0.32, indicating operational efficiency.
Year-over-year revenue growth of 18.4% highlights sustained business expansion in the medical robotics sector.
Net margin of 28.45% and return on equity of 16.91% reflect robust profitability and capital allocation.
Multiple institutional investors, including Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes significantly in recent quarters.
Risk Factors
Director Amy Ladd sold a substantial portion of her holdings (28.69% decrease), which can sometimes signal reduced confidence or liquidity needs.
Analyst Stifel Nicolaus lowered its price target from $670 to $550, suggesting potential valuation concerns despite the buy rating.
BTIG Research reduced its price objective from $512 to $469, indicating a more conservative near-term outlook.
Royal Bank Of Canada cut its price target from $650 to $600, reflecting some caution among major financial institutions.
Intuitive Surgical (ISRG) saw significant institutional activity in recent quarters, highlighted by BSN Capital Partners reducing its stake by 41.5% to 100,000 shares worth $49.6 million. Conversely, major funds like Norges Bank, J. Stern & Co., and Northwestern Mutual Wealth Management aggressively increased their holdings, with J. Stern raising its position by over 18,500% to own more than $1.2 billion in stock.
Analyst sentiment remains mixed regarding the company's valuation. While Barclays maintains an overweight rating with a $651 price target, Deutsche Bank and HSBC have downgraded their ratings or lowered targets to the low $300s. The consensus among twenty analysts is currently a Moderate Buy with an average price target of $509.02.
Insider trading data shows recent sales by executives Iman Jeddi and Gary Loeb, who sold shares under pre-arranged Rule 10b5-1 plans. Over the last ninety days, insiders have collectively sold approximately $2.8 million in stock, though they still retain a small 0.60% ownership stake in the company.
๐ BSN Capital reduced ISRG holdings by 41.5% to 100k shares.
๐ J. Stern & Co. surged stake 18,504.6% to $1.2 billion value.
๐ Norges Bank added massive $2.86 billion position in Q4.
๐ Deutsche Bank downgraded stock with new $366 price target.
๐ผ Insiders sold 6,634 shares worth $2.8 million recently.
๐ BSN Capital Partners reduced its ISRG position by 41.5%, selling 71,000 shares to hold 100,000 shares valued at $49.6 million.
๐ Norges Bank established a new massive position worth $2.86 billion in the fourth quarter.
๐ J. Stern & Co. LLP increased its stake by 18,504.6% to own 2.13 million shares valued at $1.2 billion.
๐ Northwestern Mutual Wealth Management raised its holdings by 1,043.3% to acquire an additional 1.22 million shares.
๐ Arrowstreet Capital Limited Partnership increased its position by 95.3% in the first quarter.
๐ Deutsche Bank lowered its price target from $440 to $366 and issued a sell rating.
๐ HSBC downgraded Intuitive Surgical from a buy to a hold with a $391 price objective.
๐ Barclays maintains an overweight rating with a high $651 price target.
๐ The stock currently trades at a PE ratio of 40.47 with a market cap of $124.82 billion.
๐ผ Insiders sold a total of 6,634 shares valued at $2.8 million over the last ninety days.
Bullish Signals
Norges Bank and J. Stern & Co. increased stakes significantly.
Northwestern Mutual added 1.2M shares, up over 1,000%.
Risk Factors
Deutsche Bank and HSBC downgraded ratings or lowered price targets.
Insiders sold $2.8 million in stock over last 90 days.
Bullish Signals
Major institutional investors like Norges Bank and J. Stern & Co. have significantly increased their stakes, indicating strong confidence in the company's long-term prospects.
Northwestern Mutual Wealth Management added over 1.2 million shares to its portfolio, representing a massive increase of more than 1,000%.
Risk Factors
Deutsche Bank and HSBC have downgraded their ratings or lowered price targets, signaling potential concerns about the current valuation or growth trajectory.
Insiders sold $2.8 million worth of stock in the last ninety days, which can sometimes indicate a lack of immediate confidence at the executive level.
HSBC downgraded Intuitive Surgical (NASDAQ:ISRG) from a Buy to a Hold rating, setting a $391 target price. This move follows a series of recent analyst adjustments, including Sanford Bernstein lowering its target to $685 and Jefferies reducing its objective to $515, though the consensus remains a Moderate Buy with an average target of $509.02.
The company reported strong quarterly financial results on July 16th, beating earnings estimates with $2.80 EPS versus a consensus of $2.48 and revenue of $2.89 billion against expectations of $2.83 billion. Revenue grew 18.4% year-over-year to $2.89 billion, while the business maintained a net margin of 28.45% and a return on equity of 16.91%, demonstrating robust profitability.
Despite positive earnings, insider selling activity was notable in June, with EVP Gary Loeb and SVP Iman Jeddi executing pre-arranged Rule 10b5-1 sales totaling over $2.5 million. Conversely, institutional investors showed significant accumulation in the fourth quarter, with Norges Bank, J. Stern & Co., and Northwestern Mutual increasing their stakes substantially.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which are deployed in hospitals globally for minimally invasive procedures. The company's business model relies on selling systems, instruments, and proprietary software while providing essential training and servicing support to maintain high margins and recurring revenue streams.
๐ HSBC downgraded stock to Hold with $391 target.
๐ Q2 EPS beat estimates at $2.80 vs $2.48 consensus.
๐ฐ Revenue surged 18.4% YoY to reach $2.89 billion.
๐ก๏ธ Net margin remains strong at 28.45%.
๐ฆ Major institutions increased holdings in Q4.
๐ HSBC downgraded Intuitive Surgical from Buy to Hold with a $391 target price following recent analyst skepticism.
๐ The company beat Q2 earnings estimates significantly, reporting $2.80 EPS compared to the consensus of $2.48.
๐ฐ Revenue reached $2.89 billion for the quarter, representing an 18.4% year-over-year increase.
๐ก๏ธ Intuitive Surgical maintained a healthy net margin of 28.45% and a return on equity of 16.91%.
๐ Insider selling occurred in June as EVP Gary Loeb and SVP Iman Jeddi sold shares under pre-arranged trading plans.
๐ฆ Major institutional investors including Norges Bank and J. Stern & Co. significantly increased their holdings in Q4.
๐ฌ The firm is best known for its da Vinci surgical systems used for minimally invasive procedures globally.
๐ Analyst consensus remains Moderate Buy with an average price target of $509.02 despite recent downgrades.
Bullish Signals
Revenue hit $2.89B, beating estimates of $2.83B.
EPS reached $2.80, surpassing the $2.48 consensus.
HSBC downgraded stock to Hold with lowered $391 target.
Analysts Bernstein and Jefferies reduced targets to $685 and $515.
Insiders sold 6,634 shares worth $2.79 million last quarter.
Bullish Signals
Intuitive Surgical reported quarterly revenue of $2.89 billion, surpassing analyst estimates of $2.83 billion by a notable margin.
The company achieved an EPS of $2.80, beating the consensus estimate of $2.48 by $0.32, indicating strong operational execution.
Revenue grew 18.4% year-over-year, demonstrating continued market expansion and demand for robotic surgical systems.
Net margins remained robust at 28.45%, reflecting the company's high-margin business model and pricing power.
Return on equity stood at 16.91%, highlighting efficient capital deployment and strong shareholder value generation.
Significant institutional accumulation occurred in Q4, with Norges Bank purchasing a stake worth approximately $2.86 billion.
Risk Factors
HSBC downgraded the stock from Buy to Hold, citing concerns that may be reflected in their lowered $391 target price.
Multiple other analysts recently reduced price targets, including Sanford Bernstein dropping its target to $685 and Jefferies to $515.
Corporate insiders sold a total of 6,634 shares worth $2.79 million in the last quarter, signaling potential lack of confidence at the executive level.
Intuitive Surgical (ISRG) EVP Mark Brosius sold 28 shares of the company's stock on July 29th for a total value of $10,085.88 at an average price of $360.21 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a 2.07% decrease in his direct ownership position, leaving him with 1,322 shares valued at approximately $476,198.
The company recently reported strong quarterly financial results announced on July 16th, beating analyst expectations for both earnings per share and revenue. Intuitive Surgical posted EPS of $2.80 compared to a consensus of $2.48 and generated revenue of $2.89 billion against an estimate of $2.83 billion. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%.
Institutional investor activity shows mixed signals with several funds increasing their stakes in the fourth quarter, including North Star Investment Management Corp which raised its position by 8.5%. However, analyst sentiment has softened recently, with Goldman Sachs lowering its price target to $558 and BTIG Research reducing its target from $512 to $469 while maintaining a buy rating.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which are used in minimally invasive procedures at hospitals and surgical centers globally. The company's stock currently trades at a price-to-earnings ratio of 40.45 with an average analyst target price of $517.21 based on ratings from twenty-one analysts.
๐ EVP sold 28 shares for $10,085.88 on July 29th.
๐ฐ Q3 EPS hit $2.80, beating estimates by $0.32.
๐ Revenue reached $2.89 billion, up 18.4% year-over-year.
๐ฆ Institutional ownership is 83.64%; North Star added 8.5%.
๐ Goldman Sachs lowered target to $558; BTIG cut to $469.
๐ EVP Mark Brosius sold 28 shares of ISRG stock for $10,085.88 under a pre-arranged Rule 10b5-1 trading plan on July 29th.
๐ฐ The company reported Q3 EPS of $2.80, beating the consensus estimate of $2.48 by $0.32.
๐ Revenue reached $2.89 billion for the quarter, representing an 18.4% increase year-over-year.
๐ฆ Institutional ownership remains high at 83.64%, with North Star Investment Management increasing its stake by 8.5% in Q4.
๐ Goldman Sachs lowered its price target to $558, while BTIG Research reduced its target from $512 to $469.
๐ The stock trades at a P/E ratio of 40.45 with an average analyst target price of $517.21.
๐ฌ Intuitive Surgical is best known for its da Vinci surgical systems used in minimally invasive procedures.
Bullish Signals
Beat EPS expectations with $2.80 vs $2.48 consensus.
Revenue grew robustly 18.4% YoY to $2.89 billion.
Strong profitability: 28.45% net margin and 16.91% ROE.
Institutional investors added holdings, including North Star +8.5%.
Risk Factors
Goldman Sachs and BTIG Research recently reduced price targets.
Stock trades below 50-day ($353.10) and 200-day ($454.32) averages.
Bullish Signals
Intuitive Surgical beat earnings expectations significantly, reporting $2.80 EPS versus the consensus of $2.48.
Revenue growth was robust at 18.4% year-over-year, reaching $2.89 billion for the quarter.
The company maintains strong profitability with a net margin of 28.45% and a return on equity of 16.91%.
Several institutional investors increased their holdings in Q4, including North Star Investment Management Corp which added 8.5% to its position.
Risk Factors
Analyst price targets have been reduced recently by Goldman Sachs and BTIG Research, indicating some caution on valuation levels.
The stock is trading below its 50-day and 200-day moving averages at $353.10 versus $401.70 and $454.32 respectively.
Intuitive Surgical (ISRG) shares fell 37% to $355 following Q2 earnings, where the company beat revenue estimates with 19% growth and non-GAAP EPS of $2.80. Despite the financial beat, management cut full-year procedure growth guidance for the da Vinci system to a range of 13.5%-15.5%, down from 18% in 2025, causing an 11% single-day drop in stock price.
The decline is attributed to specific headwinds including U.S. procedure deceleration due to ACA premium dynamics and GLP-1 drug usage reducing bariatric cases, alongside tariff exposure from manufacturing in Mexico, Germany, and China. Management repurchased $379 million of stock in Q2 at an average price above the current market level, while maintaining a robust cash position of $8.6 billion.
Analyst sentiment remains mixed but constructive long-term. Bernstein maintains an Outperform rating with a target of $685, citing the da Vinci 5 upgrade cycle and recurring revenue durability. However, the consensus price target sits at $484, implying roughly 36% upside from current levels as investors weigh near-term volatility against the company's dominant market position and fortress balance sheet.
๐ ISRG shares fell 37% YTD after procedure growth guidance cut to 13.5%-15.5%.
๐ฐ Q2 revenue hit $2.89B, beating estimates with non-GAAP EPS of $2.80.
๐ก๏ธ Management repurchased $379M in Q2 while holding $8.6B cash on hand.
๐ U.S. da Vinci growth slowed to 12% due to GLP-1 impacts and payer dynamics.
๐ International procedures surged 21%, with Europe and Asia both growing 20%.
๐ ISRG shares dropped 37% year-to-date to $355 after management cut full-year procedure growth guidance to 13.5%-15.5%.
๐ฐ Company beat Q2 estimates with $2.89B revenue (up 18.54%) and non-GAAP EPS of $2.80, topping the consensus.
๐ก๏ธ Management repurchased $379 million in Q2 at an average price of $439, above the current trading level.
๐ธ The company holds a strong balance sheet with $8.6 billion in cash on hand.
๐ U.S. da Vinci procedure growth slowed to 12% in Q2 from 14% in Q1 due to payer dynamics and GLP-1 impacts.
๐ International procedures grew 21%, with Europe and Asia both posting 20% growth.
๐ง Non-GAAP gross margin expanded to 70.0%, aided by a $36 million tariff refund.
๐ค Da Vinci 5 placements reached 246 of 468 total, representing a 24% increase in U.S. placements.
๐ Recurring revenue now accounts for approximately 85% of the company's total revenue.
๐ฏ Bernstein analyst targets $685 (92% upside), while the average Wall Street target is $484 (36% upside).
โ ๏ธ Tariff exposure across Mexico, Germany, and China manufacturing compressed valuation multiples.
๐ CEO Dave Rosa cited high-single-digit declines in bariatric cases from GLP-1 usage as a key factor.
Bullish Signals
Revenue grew 19% YoY to $2.89 billion.
Non-GAAP EPS of $2.80 beat consensus.
$379 million stock repurchase executed in Q2.
$8.6 billion cash reserves on balance sheet.
International procedures surged 21% in Q2.
Risk Factors
Guidance cut to 13.5%-15.5%, down from 18% in 2025.
U.S. da Vinci growth slowed to 12% in Q2.
Bariatric cases declined due to GLP-1 drug competition.
Tariffs in Mexico, Germany, and China compress valuation.
Stock fell 37% YTD despite underlying business growth.
Bullish Signals
ISRG beat Q2 estimates for the fifth consecutive quarter with revenue growing 19% year-over-year to $2.89 billion.
Non-GAAP EPS of $2.80 significantly topped the consensus estimate of $2.5037.
Management executed a $379 million stock repurchase in Q2 at an average price of $439, well above the current share price.
The company maintains a fortress balance sheet with $8.6 billion in cash reserves.
International procedures grew 21% in Q2, demonstrating strong global demand outside the U.S.
Non-GAAP gross margin expanded to 70.0%, supported by a $36 million tariff refund and operational efficiency.
Da Vinci 5 placements surged 24% in the U.S., indicating successful adoption of the newer robotic platform.
Recurring revenue now comprises roughly 85% of total revenue, providing high durability and predictability.
Bernstein maintains an Outperform rating with a $685 price target, citing the da Vinci 5 upgrade cycle as a key driver.
Risk Factors
Management cut full-year procedure growth guidance to 13.5%-15.5%, down from 18% in 2025.
U.S. da Vinci procedure growth decelerated to 12% in Q2 from 14% in the prior quarter.
Bariatric cases faced high-single-digit declines due to reduced demand from GLP-1 weight loss drug usage.
Tariff exposure across manufacturing hubs in Mexico, Germany, and China compressed valuation multiples.
The stock has fallen 37% year-to-date despite the underlying business continuing to grow.
Analyst consensus price target of $484 implies a 36% gap from current levels, reflecting near-term uncertainty.
Intuitive Surgical (ISRG) shares rose 5.82% to $357.15 following the announcement of a new patient awareness collaboration with Deion Sanders, known as Coach Prime. The partnership leverages Sanders' personal experience undergoing robotic-assisted surgery for bladder cancer to educate patients about surgical options and encourage informed discussions with physicians.
The initiative focuses on providing educational resources through the da Vinci surgical platform to help patients understand treatment considerations before making decisions. Intuitive Surgical's Chief Medical Officer, Jaime Wong, emphasized that the campaign prioritizes education over direct treatment promotion to support meaningful conversations between patients and healthcare providers regarding complex medical choices.
Intuitive Surgical maintains its position as the global leader in robotic-assisted minimally invasive surgery, having facilitated more than 20 million procedures worldwide using its da Vinci systems. The company highlights that trained surgeons utilize these platforms to perform precise, less invasive operations which can lead to fewer complications and shorter recovery periods for patients.
Despite the stock price increase, the article does not cite specific financial metrics such as revenue growth, earnings beats, or new contract values associated with this partnership. The news is primarily driven by brand visibility and public relations efforts rather than reported changes in company economics or operational performance.
๐ ISRG stock rose 5.82% to $357.15 after new campaign announcement.
๐ค Deion Sanders promotes robotic surgery using his personal bladder cancer experience.
๐ฉบ Educational resources via da Vinci platform aid patient decision-making.
๐ Over 20 million robotic-assisted procedures completed globally with da Vinci system.
โ ๏ธ No specific financial data links campaign to revenue or margin impacts.
๐ ISRG stock price increased 5.82% to close at $357.15 after announcing the new awareness campaign.
๐ค The partnership features Deion Sanders ('Coach Prime') to promote understanding of robotic-assisted surgery options.
๐ฉบ The campaign utilizes Coach Prime's personal experience with da Vinci surgery for bladder cancer as a case study.
๐ Intuitive Surgical plans to distribute educational resources via its da Vinci platform to assist patient decision-making.
๐จโโ๏ธ Chief Medical Officer Jaime Wong stated the initiative aims to facilitate better discussions between patients and doctors.
๐ The company reports over 20 million robotic-assisted procedures completed globally using the da Vinci system.
๐ฌ Robotic systems are noted for enabling more precise, less invasive procedures with potential recovery benefits.
โ ๏ธ The article lacks specific financial data linking this PR campaign to revenue or margin impacts.
Bullish Signals
Stock price gained 5.82% after partnership announcement.
Over 20 million procedures completed worldwide.
New initiative strengthens brand reputation.
Deion Sanders partnership boosts public awareness.
Risk Factors
No concrete financial metrics like revenue or earnings provided.
Campaign focuses on patient education, not new products.
Reliance on single endorsement limits long-term strategic impact.
Bullish Signals
Stock price gained 5.82% immediately following the announcement of the high-profile partnership.
Company reinforces its market leadership status by citing over 20 million completed procedures worldwide.
New educational initiative may strengthen brand reputation and patient trust in robotic surgery options.
Partnership with a high-visibility figure like Deion Sanders increases public awareness of the technology.
Risk Factors
Article does not provide concrete financial metrics (revenue, earnings, or guidance) to substantiate the stock gain.
Campaign focuses on patient education rather than new product launches or operational expansions.
Reliance on a single high-profile endorsement may limit long-term strategic impact compared to organic growth drivers.
Alamar Capital Management LLC acquired a new stake in Intuitive Surgical, Inc. (ISRG) during the first quarter, purchasing 3,563 shares valued at approximately $1.64 million. This filing highlights continued institutional interest alongside other funds like Fiduciary Financial Group and North Star Investment Management, which increased their positions by 2.1% and 8.5% respectively in the fourth quarter. Overall, institutional ownership remains high at 83.64%, indicating strong confidence from major investors despite recent price fluctuations.
Analyst sentiment regarding ISRG is mixed but leans positive with a consensus 'Moderate Buy' rating and an average price target of $523.46. While TD Cowen, Citigroup, and Robert W. Baird have recently lowered their price objectives to between $500 and $520, Goldman Sachs maintains a higher target of $558. The stock currently trades around $340.69, significantly below its 50-day moving average of $410.47 and 200-day average of $462.47, suggesting potential volatility or undervaluation relative to recent performance metrics.
Insider trading activity shows a net reduction in ownership by key executives and directors during the last quarter. EVP Gary Loeb sold 400 shares worth approximately $169,656 under a pre-arranged Rule 10b5-1 plan, while Director Amy L. Ladd reduced her holdings by 67.66% in a similar transaction. Collectively, insiders sold over 7,169 shares valued at more than $3 million, bringing total insider ownership down to 0.60% of the outstanding stock.
๐ Alamar Capital bought 3,563 ISRG shares worth $1.64M in Q1.
๐ Institutional ownership is 83.64%, with North Star increasing stakes by 8%.
๐ Stock trades below 50-day ($410.47) and 200-day ($462.47) averages.
๐ฏ Analysts rate it 'Moderate Buy' with a $523.46 average price target.
๐ Insiders sold 7,169 shares worth over $3M, dropping ownership to 0.60%.
๐ Alamar Capital Management LLC acquired a new stake in Intuitive Surgical (ISRG) in Q1, purchasing 3,563 shares valued at approximately $1.64 million.
๐ Institutional ownership of ISRG stands at 83.64%, with several funds like North Star Investment Management increasing their stakes by over 8% in the fourth quarter.
๐ The stock opened at $340.69, trading well below its 50-day moving average of $410.47 and 200-day average of $462.47.
๐ฏ Analyst consensus is a 'Moderate Buy' with an average price target of $523.46, though recent targets from TD Cowen and Citigroup have been lowered to the $500-$520 range.
๐ EVP Gary Loeb sold 400 shares worth $169,656 in June, while Director Amy L. Ladd sold 500 shares worth $236,730 in April under pre-arranged trading plans.
๐ Total insider selling reached 7,169 shares valued at over $3 million in the last quarter, reducing insider ownership to just 0.60% of the company's stock.
Bullish Signals
83.64% institutional ownership with new Alamar Capital acquisitions.
Risk Factors
Executives sold over $3M in shares last quarter.
Analysts lowered price targets to $500-$520.
Bullish Signals
Strong institutional backing with 83.64% of shares held by institutional investors, including significant new acquisitions from Alamar Capital Management LLC.
Analyst consensus remains 'Moderate Buy' with an average price target of $523.46, suggesting potential upside from current levels around $340.
Risk Factors
Recent insider selling activity is notable, with executives and directors collectively offloading over $3 million in shares during the last quarter.
Several major analysts have recently lowered their price targets to between $500 and $520, indicating some near-term caution or valuation concerns.
Shares of Intuitive Surgical (NASDAQ:ISRG) hit a new 52-week low around $346 on Monday, driven by JPMorgan Chase lowering its price target from $550 to $450 while maintaining an overweight rating. The stock has faced mixed analyst sentiment recently, with Deutsche Bank cutting its target to $366 and assigning a 'sell' rating, though other firms like Stifel Nicolaus and Wall Street Zen have raised targets or upgraded ratings to 'buy'.
Despite the recent price decline, Intuitive Surgical reported strong quarterly financial results on July 16th. The company posted revenue of $2.89 billion, beating estimates by $57 million, with earnings per share (EPS) of $2.80 versus a consensus of $2.48. Revenue grew 18.4% year-over-year, and the firm maintained healthy margins at 28.45% and a return on equity of 17.09%.
Institutional ownership remains high at 83.64%, with several hedge funds increasing their stakes in the fourth quarter, including North Star Investment Management Corp which raised its position by 8.5%. The company's market capitalization stands at approximately $124 billion, trading below its 50-day and 200-day moving averages, reflecting current market caution despite solid operational performance.
๐ ISRG shares hit 52-week low of $346.10 after analyst downgrades.
๐ฐ Q2 revenue surged 18.4% to $2.89 billion, beating expectations.
๐ EPS reached $2.80, surpassing consensus by $0.32.
๐ฆ Institutional ownership stands strong at 83.64%.
๐ฎ Full-year EPS projected at $8.61.
๐ ISRG shares hit a new 52-week low of $346.10 following JPMorgan's price target reduction from $550 to $450.
๐ Deutsche Bank downgraded the stock to 'sell' with a lowered price target of $366, contrasting with recent upgrades from Stifel and Wall Street Zen.
๐ฐ The company reported Q2 revenue of $2.89 billion, an 18.4% year-over-year increase that beat analyst expectations.
๐ EPS reached $2.80 for the quarter, surpassing the consensus estimate of $2.48 by $0.32.
๐ฆ Institutional ownership is robust at 83.64%, with multiple hedge funds increasing their holdings in Q4.
๐ The stock trades below its 50-day moving average ($412.30) and 200-day moving average ($464.06).
๐ต Net margins remain strong at 28.45% with a return on equity of 17.09%.
๐ฎ Analysts project full-year EPS of $8.61 for the current fiscal year.
๐ฅ Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems.
Bullish Signals
Revenue grew 18.4% YoY to $2.89 billion.
EPS of $2.80 beat estimates by $0.32.
Net margins at 28.45% and ROE at 17.09%.
Institutional ownership reached 83.64% with stake increases.
Upgraded to 'buy' by Wall Street Zen.
Risk Factors
JPMorgan lowered target to $450 as stock hit 52-week low.
Deutsche Bank cut target to $366 with a sell rating.
Stock trades below 50-day ($412.30) and 200-day ($464.06) averages.
Mixed outlook with seven holds, one sell, and some buys.
Bullish Signals
Revenue grew 18.4% year-over-year to $2.89 billion, significantly beating analyst expectations of $2.83 billion.
The company reported EPS of $2.80, which exceeded the consensus estimate of $2.48 by $0.32.
Net margins remained healthy at 28.45% and return on equity stood at 17.09%.
Several institutional investors increased their stakes in Q4, including North Star Investment Management Corp raising its position by 8.5%.
Wall Street Zen upgraded the stock from 'hold' to 'buy', and Stifel Nicolaus lowered its target while maintaining a 'buy' rating.
The company maintains a dominant market position with high institutional ownership at 83.64%.
Risk Factors
JPMorgan Chase lowered its price target from $550 to $450, contributing to the stock hitting a new 52-week low.
Deutsche Bank cut its price target to $366 and assigned a 'sell' rating, indicating bearish sentiment among some analysts.
The stock is currently trading below both its 50-day simple moving average ($412.30) and 200-day simple moving average ($464.06).
Analyst consensus includes seven 'Hold' ratings and one 'Sell' rating alongside the Buy ratings, reflecting mixed outlooks.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)